 |
Donna L. Mendrick
[Scientific Fellow and Vice President, Toxicogenomics
Gene Logic Inc.]
|
|
Presentation Title
Pharmacogenomic Biomarker Discovery
Presentation Category
Pharmacogenomics as a tool in Pre-Clinical Development
|
Contact
Gene Logic Inc.
610 Professional Drive
Gaithersburg, MD 20879
Telephone: 301.987.1700
Toll Free: 800.GENELOGIC
(800.436.3564)
Int: +1.301.987.1709
Fax. 301.987.1701
» Sponsor Showcase
|
|
Biography
Dr. Mendrick, Scientific Fellow and Vice President of Toxicogenomics at Gene Logic, has twenty-five years of experience in the fields of pharmacogenomics, toxicology, pharmacology, immunology and pathology with in vivo and in vitro systems. She joined Gene Logic in 1998 to spearhead its toxicogenomics effort and formed a pharmaceutical consortium to help guide the development of the program. Dr. Mendrick served as a member of the planning committee for the last three of the FDA co-sponsored Workshops on the use of pharmacogenomic data in the regulatory environment. She is a member of the Predictive Toxicology program committee at the New York Academy of Sciences and co-chaired its inaugural meeting on November 14, 2005. She has spoken on the use of pharmacogenomics to wide-ranging audiences including the FDA-PhRMA-AASLD Hepatotoxicity Steering Committee (January 2005), a PAM/EFPIA Workshop on Toxicogenomics (October 2004), the Woodrow Wilson International Center for Scholars (November, 2002), the Committee on Emerging Issues and Data on Environmental Contaminants at The National Academy of Sciences (February, 2003 and August, 2004), the PhRMA/FDA Genomics (Microarray) Biostatistics Workshop held in April of 2004, and the EPA Science Forum (May 2003). Dr. Mendrick was a member of the Editorial Board of the Journal of Histochemistry and Cytochemistry for 8 years, a member of the NIH SBIR Immunology Study Section for 8 years, and a member of the Board of Directors of the National Kidney Foundation of Massachusetts for 4 years. Prior to joining Gene Logic in 1998, Dr. Mendrick was a Group Leader in Pharmacology at Human Genome Sciences Inc. where she directed several Project Teams and planned and supervised pharmacology and toxicology experiments. Prior to joining Human Genome Sciences she was an Assistant Professor in the Department of Pathology at Harvard Medical School where her research focused on renal immunopathology and endothelial biology.
|
|
Abstract
Bridging Biomarkers. A recent study by the ILSI group (Regul Toxicol Pharmacol 32:56, 2000) demonstrated the need for improved safety testing prior to human exposure. Clearly, better biomarkers of organ toxicity are needed in both preclinical and clinical arenas to protect human safety. This presentation will focus on in silico approaches that can be used to discover and qualify potential biomarkers that bridge preclinical and clinical testing to provide better tools to identify safety risks to patients.
|
